Who is sponsoring NCT01472653?

NCT01472653 is sponsored by Institute of Oncology Ljubljana.

What condition does NCT01472653 study?

NCT01472653 studies Head and Neck Cancer.

What drugs are being tested in NCT01472653?

Interventions: cisplatin, radiotherapy, cetuximab.

What is the status of NCT01472653?

NCT01472653 is currently UNKNOWN.

Last reviewed 2011-12-11 · How we verify

Skin Reaction to Cetuximab as Criteria for Treatment Selection in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck: Phase 2 Study

NCT01472653 Phase 2 UNKNOWN

The therapy of patients with locally advanced head and neck cancer will be adjusted to the grade of skin rush as recorded after the first two cycles of Cetuximab and Cisplatin, i.e. either with radioimmunotherapy (radiotherapy and Cetuximab) or radiochemotherapy (radiotherapy and Cisplatin.

Details

Lead sponsor	Institute of Oncology Ljubljana
Phase	Phase 2
Status	UNKNOWN
Enrolment	120
Start date	2011-12
Completion	2016-12

Conditions

Head and Neck Cancer

Interventions

cisplatin
radiotherapy
cetuximab

Primary outcomes

locoregional complete response rate — 12-14 weeks after therapy
The primary objective of the study is to determine radiologically the complete response rate 12-14 weeks after therapy.

Countries

Slovenia